Biotech firm

生物技术公司

Biocon on Tuesday said it has received approval from the government authorities for a

Biocon公司周二表示，已获得政府当局的批准。

generic diabetes medication

通用糖尿病药物

.

。

The company has received approval for its

公司已获得其批准

Liraglutide

利拉鲁肽

drug substance and its wholly-owned subsidiary

药物实体及其全资子公司

Biocon

百康生物制药公司

Pharma has received approval for its Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge), from the Drugs Controller General of India (

印度药品管理局（Drugs Controller General of India）已批准Pharma公司生产的利拉鲁肽药物产品（预填充笔和药筒中的6毫克/毫升注射液）。

CDSCO

中央药品标准控制组织

).

）。

The approval is for the generic version of

批准是针对通用版本的

Victoza

Victoza

, indicated for the treatment of insufficiently controlled

，适用于控制不足的治疗

Type 2 Diabetes Mellitus

2型糖尿病 Mellitus

in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise, the company said in a regulatory filing.

该公司在一份监管文件中表示，适用于10岁及以上的成人、青少年和儿童，作为饮食和运动的辅助手段。

'The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes,'

“我们首个垂直整合的GLP-1药物——利拉鲁肽在印度获得批准，这是扩大糖尿病患者获取该药物的又一重要进展。”

Biocon

百康

CEO and MD Siddharth Mittal said.

首席执行官兼董事总经理西达尔特·米塔尔表示。

India has one of the highest number of people with diabetes globally, with estimates exceeding 77 million cases, and expected to rise further, he added.

他补充说，印度是全球糖尿病人数最多的国家之一，估计超过7700万例，而且预计还会进一步增加。

Live Events

现场活动

'We are now gearing up to launch the product expeditiously through our commercialisation partners in India,' Mittal stated.

米塔尔表示：“我们现在正准备通过我们在印度的商业化合作伙伴迅速推出该产品。”

Biocon shares were trading 0.81 per cent up at Rs 336.75 apiece on BSE.

Biocon的股票在BSE上每股交易价格为336.75卢比，上涨了0.81%。

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)